Skip to content

Author

P. Karschnia

6 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

BIOM-14 Patterns, risk factors and management of CD19-directed Chimeric Antigen Receptor T-cell therapy failure in CNS lymphoma

CD19-directed chimeric antigen receptor T-cell therapy (CD19-CAR) demonstrates encouraging activity in CNS lymphoma (CNSL), yet most patients ultimately develop progressive disease (PD). Predictors, radiographic patterns, and optimal salvage strategies after CD19-CAR failure remain poorly defined. We retrospectively...

L. Kaulen, P. Karschnia, S. Doubrovinskaia et al. · 0 citations
Open access Sep 2026

Supplementary motor area syndrome in intracranial gliomas is not associated with worse survival

Resection of gliomas involving the supplementary motor area (SMA) carries a substantial risk of postoperative functional deficits, which may affect patients’ ability to undergo adjuvant therapy. This study evaluated whether postoperative SMA syndrome is associated with delayed initiation of adjuvant therapy and with pr...

Dragan Janković, S. Rosenke, J. Blobner et al. · 0 citations
Open access Oct 2026

Longitudinal spatial changes of the contralesional corticospinal tract in high-grade glioma: a within-patient DTI tractography study

The contralesional corticospinal tract (CST) is often used as an internal reference in glioma tractography, but its longitudinal stability remains poorly understood. We explored within-patient changes in contralesional CST characteristics between primary and recurrent high-grade glioma. Twenty-nine patients with paired...

Bing-Zheng Li, R. Liang, Ghaith Altawalbeh et al. · 0 citations
Open access Oct 2026

Liquid biopsy using circulating miRNAs for the identification of recurrence-associated biomarkers in glioblastoma CNS WHO grade 4

Glioblastoma CNS WHO Grade 4 (GBM) is associated with poor prognosis and high recurrence rates despite the current therapeutic approaches. Conventional imaging, in particular Magnetic Resonance Imaging (MRI), is primarily used during follow-up to detect tumor recurrence but has limited ability to distinguish recurr...

R. Muhtadi, Christian D. Diehl, N. Schmid et al. · 0 citations
Open access Sep 2026

Supplementary motor area syndrome in intracranial gliomas is not associated with worse survival

Resection of gliomas involving the supplementary motor area (SMA) carries a substantial risk of postoperative functional deficits, which may affect patients’ ability to undergo adjuvant therapy. This study evaluated whether postoperative SMA syndrome is associated with delayed initiation of adjuvant therapy and with pr...

Dragan Janković, S. Rosenke, J. Blobner et al. · 0 citations
Sep 2026

Identification of prognostically relevant residual tumor in glioblastoma after surgery: A comparative analysis of MR-based RANO resect classes vs. [18F]FET PET.

BACKGROUND Assessment of postoperative tumor burden is essential in IDH-wildtype glioblastoma. The RANO resect classification stratifies patients based on residual tumor volume on postoperative MRI. [¹⁸F]FET PET can detect metabolically active tumor-suspicious tissue invisible on MRI. Its additional prognostic contribu...

J. Blobner, Katharina J. Schmidbauer, M. Müther et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.